Skip to main content
Top
Published in: Current Osteoporosis Reports 1/2012

01-03-2012 | Current Therapeutics (SL Silverman, Section Editor)

Assessment of Fracture Risk

Authors: Sanford Baim, William D. Leslie

Published in: Current Osteoporosis Reports | Issue 1/2012

Login to get access

Abstract

Osteoporosis-related fractures (low-trauma, fragility fractures) are associated with significant morbidity, mortality, and health care expenditure worldwide. In the absence of a defining fracture, the diagnosis of osteoporosis is based on the World Health Organization’s T-score criteria using central dual-energy x-ray absorptiometry (DXA). Paradoxically, the majority of those patients who will sustain a low-trauma fracture do not meet the T-score definition of osteoporosis. Conversely, younger individuals with bone density in the osteoporotic range but no other risk factors have relatively low fracture rates and yet are frequently considered candidates for osteoporosis therapies. The limited accuracy of bone density testing alone to predict fractures has led to the development of a variety of fracture assessment tools that utilize the combination of bone density and clinical risk factors to improve the prediction of low-trauma fractures. These fracture assessment tools quantitatively predict the 10-year fracture probability of hip and major osteoporosis-related fractures, and can be used to define cost-effective intervention strategies for primary and secondary fracture prevention.
Literature
1.
go back to reference •• National Osteoporosis Foundation, Clinician’s Guide to prevention and treatment of osteoporosis. 2008; available at http//nof.org/professionals/NOF_clinicians_Guide pdf, accessed February 12, 2011. The NOF Clinician’s Guide to prevention and treatment of osteoporosis serves as a basic reference for the evaluation and treatment of osteoporosis in the United States. •• National Osteoporosis Foundation, Clinician’s Guide to prevention and treatment of osteoporosis. 2008; available at http//nof.org/professionals/NOF_clinicians_Guide pdf, accessed February 12, 2011. The NOF Clinician’s Guide to prevention and treatment of osteoporosis serves as a basic reference for the evaluation and treatment of osteoporosis in the United States.
2.
go back to reference Kanis JA. 2007 WHO Technical Report, University of Sheffield, UK:66. Kanis JA. 2007 WHO Technical Report, University of Sheffield, UK:66.
3.
go back to reference Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726.PubMedCrossRef Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726.PubMedCrossRef
4.
go back to reference Gullber B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407.CrossRef Gullber B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407.CrossRef
6.
go back to reference Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;3:465–75. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;3:465–75.
7.
go back to reference World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO; 1994. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO; 1994.
8.
go back to reference Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:17-1141. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:17-1141.
9.
go back to reference Kanis JA, Johnell O, Oden A, Jonsson B, et al. Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone. 2000;27:585–90.PubMedCrossRef Kanis JA, Johnell O, Oden A, Jonsson B, et al. Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone. 2000;27:585–90.PubMedCrossRef
10.
go back to reference World Health Organization Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO; 1998. World Health Organization Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO; 1998.
11.
go back to reference Marshall D, Johnell O, Edel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–59.PubMedCrossRef Marshall D, Johnell O, Edel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–59.PubMedCrossRef
12.
go back to reference Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med. 1994;87:203–9.PubMed Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med. 1994;87:203–9.PubMed
13.
go back to reference Kanis JA, Borgstrom F, De laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581–9.PubMedCrossRef Kanis JA, Borgstrom F, De laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581–9.PubMedCrossRef
14.
go back to reference Lewiecki EM, Compston JE, Miller PD, et al. 2010 Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom. 2011;14:226–36.PubMedCrossRef Lewiecki EM, Compston JE, Miller PD, et al. 2010 Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom. 2011;14:226–36.PubMedCrossRef
15.
go back to reference Leslie WD, Tsang JF, Caetano PA, et al. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007;92(1):77–81.PubMedCrossRef Leslie WD, Tsang JF, Caetano PA, et al. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007;92(1):77–81.PubMedCrossRef
16.
go back to reference Wainwright SA, Marshall LM, Ensrud KE, et al. Study of Osteoporotic Fractures Research Group. Hip fractures in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–93.PubMedCrossRef Wainwright SA, Marshall LM, Ensrud KE, et al. Study of Osteoporotic Fractures Research Group. Hip fractures in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–93.PubMedCrossRef
17.
go back to reference Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9):1404–9.PubMedCrossRef Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9):1404–9.PubMedCrossRef
18.
go back to reference Sornay-Rendu E, Muoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture. The OFELY study. J Bone Miner Res. 2005;20(10):1813–19.PubMedCrossRef Sornay-Rendu E, Muoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture. The OFELY study. J Bone Miner Res. 2005;20(10):1813–19.PubMedCrossRef
19.
go back to reference Alonso-Coello P, García-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 2008;19;336(7636):126–9. Alonso-Coello P, García-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 2008;19;336(7636):126–9.
20.
go back to reference Lewiecki M. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13(4):335–45.PubMedCrossRef Lewiecki M. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13(4):335–45.PubMedCrossRef
21.
go back to reference Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment a randomized trial. Ann Intern Med. 2011;155:87–96.PubMed Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment a randomized trial. Ann Intern Med. 2011;155:87–96.PubMed
22.
go back to reference Leslie WD. Absolute fracture risk reporting in clinical practice: a physician-centered survey. Osteoporos Int. 2008;19:459–63.PubMedCrossRef Leslie WD. Absolute fracture risk reporting in clinical practice: a physician-centered survey. Osteoporos Int. 2008;19:459–63.PubMedCrossRef
23.
go back to reference Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl2):S407–13.PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl2):S407–13.PubMedCrossRef
24.
go back to reference Papaionnou A, Morin S, Cheung AM, et al. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864–73.CrossRef Papaionnou A, Morin S, Cheung AM, et al. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864–73.CrossRef
25.
go back to reference Hamdy RC, Baim S, Broy SB. Algorithm for the management of osteoporosis. SMJ. 2010;103(10):1009–15.CrossRef Hamdy RC, Baim S, Broy SB. Algorithm for the management of osteoporosis. SMJ. 2010;103(10):1009–15.CrossRef
29.
go back to reference Hippisley-Cox J, Copuland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229 available at http://www.qfracture.org/, accessed February 24, 2011. Hippisley-Cox J, Copuland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229 available at http://​www.​qfracture.​org/​, accessed February 24, 2011.
30.
go back to reference Kanis JA on behalf of the World Health Organization Scientific Group a, Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. 2008, available at http://www.shef.ac.uk/FRAX/index.htm, accessed February 24, 2011. Kanis JA on behalf of the World Health Organization Scientific Group a, Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. 2008, available at http://​www.​shef.​ac.​uk/​FRAX/​index.​htm, accessed February 24, 2011.
31.
go back to reference Oden A, Johansson H, McCloskey EV. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRef Oden A, Johansson H, McCloskey EV. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRef
32.
go back to reference Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRef Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRef
33.
go back to reference •• Hans D, Kanis J, Baim S, et al. Joint official positions of the International Society for Clinical Densitometry (ISCD) and International Osteoporosis Foundation (IOF) on FRAX®: Executive Summary of the 2010 Position Development Conference on Interpretation and Use of FRAX® in Clinical Practice. J Clin Densitom 2011;14(3):171–80. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient. PubMedCrossRef •• Hans D, Kanis J, Baim S, et al. Joint official positions of the International Society for Clinical Densitometry (ISCD) and International Osteoporosis Foundation (IOF) on FRAX®: Executive Summary of the 2010 Position Development Conference on Interpretation and Use of FRAX® in Clinical Practice. J Clin Densitom 2011;14(3):171–80. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient. PubMedCrossRef
34.
go back to reference •• Kanis J, Hans D, Cooper C, et al. Interpretation and use of FRAX® in clinical practice. Osteoporos Int 2011;22(9):2395–411. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient. PubMedCrossRef •• Kanis J, Hans D, Cooper C, et al. Interpretation and use of FRAX® in clinical practice. Osteoporos Int 2011;22(9):2395–411. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient. PubMedCrossRef
36.
go back to reference Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–46.PubMedCrossRef Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–46.PubMedCrossRef
37.
go back to reference Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–44.PubMedCrossRef Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–44.PubMedCrossRef
38.
go back to reference Cooper C, Cole ZA, Holroyd CR, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22(5):1277–88.PubMedCrossRef Cooper C, Cole ZA, Holroyd CR, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22(5):1277–88.PubMedCrossRef
39.
go back to reference Leslie WD, Lix LM. Effects of FRAX® model calibration on intervention rates: a simulation study. J Clin Densitom. 2011;14(3):272–8.PubMedCrossRef Leslie WD, Lix LM. Effects of FRAX® model calibration on intervention rates: a simulation study. J Clin Densitom. 2011;14(3):272–8.PubMedCrossRef
40.
go back to reference Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer (New York); 2008. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer (New York); 2008.
41.
go back to reference • Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011;22:817–27. This describes the creation of a FRAX model for fracture assessment in Canadian men and women.PubMedCrossRef • Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011;22:817–27. This describes the creation of a FRAX model for fracture assessment in Canadian men and women.PubMedCrossRef
42.
go back to reference Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350–8.PubMedCrossRef Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350–8.PubMedCrossRef
43.
go back to reference Fraser L-A, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int. 2011;22:829–37.PubMedCrossRef Fraser L-A, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int. 2011;22:829–37.PubMedCrossRef
46.
go back to reference Watts NB, Siris ES, Cummings SR, Bauer DC. Perspective: Filtering FRAX®. Osteoporos Int. 2010;21:537–41.PubMedCrossRef Watts NB, Siris ES, Cummings SR, Bauer DC. Perspective: Filtering FRAX®. Osteoporos Int. 2010;21:537–41.PubMedCrossRef
47.
go back to reference McCloskey E, Compston J, Cooper C. The US FRAX® filter: avoiding confusion or hindering progress? Osteoporos Int. 2010;21:885.PubMedCrossRef McCloskey E, Compston J, Cooper C. The US FRAX® filter: avoiding confusion or hindering progress? Osteoporos Int. 2010;21:885.PubMedCrossRef
48.
go back to reference •• National Osteoporosis Guideline Group (NOGG). Osteoporosis: clinical guidelines for prevention and treatment Executive Summary. 2010. The UK NOGG assessment and diagnosis of osteoporosis and therapeutic agents available for treatment provides different management strategies for the prevention and treatment of osteoporotic fractures in postmenopausal women and men over 50 years of age. •• National Osteoporosis Guideline Group (NOGG). Osteoporosis: clinical guidelines for prevention and treatment Executive Summary. 2010. The UK NOGG assessment and diagnosis of osteoporosis and therapeutic agents available for treatment provides different management strategies for the prevention and treatment of osteoporotic fractures in postmenopausal women and men over 50 years of age.
49.
go back to reference Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedCrossRef Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedCrossRef
50.
go back to reference •• Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–408. The use of a case-finding strategy for the management of osteoporosis with FRAX reviews the use of FRAX as a screening tool with and without bone density testing for the treatment of osteoporosis in the United Kingdom.PubMedCrossRef •• Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–408. The use of a case-finding strategy for the management of osteoporosis with FRAX reviews the use of FRAX as a screening tool with and without bone density testing for the treatment of osteoporosis in the United Kingdom.PubMedCrossRef
51.
go back to reference Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009;24:675–80.PubMedCrossRef Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009;24:675–80.PubMedCrossRef
52.
go back to reference Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010;21(1):41–52.PubMedCrossRef Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010;21(1):41–52.PubMedCrossRef
53.
go back to reference •• Papaioannou A, Morin S, Cheung AM, et al. for the Scientific Advisory Council of Osteoporosis Canada. 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Can Med Assoc J 2010;182(17):1864–73. The Canadian Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada reviews the use of the FRAX model in Canada in contrast to US and UK Osteoporosis Guidelines.CrossRef •• Papaioannou A, Morin S, Cheung AM, et al. for the Scientific Advisory Council of Osteoporosis Canada. 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Can Med Assoc J 2010;182(17):1864–73. The Canadian Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada reviews the use of the FRAX model in Canada in contrast to US and UK Osteoporosis Guidelines.CrossRef
54.
go back to reference Leslie WD, Berger C, Langsetmo L, Adachi JD, et al. CaMos Research Group. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba BMD cohorts. Osteoporos Int. 2011;22:1873–83.PubMedCrossRef Leslie WD, Berger C, Langsetmo L, Adachi JD, et al. CaMos Research Group. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba BMD cohorts. Osteoporos Int. 2011;22:1873–83.PubMedCrossRef
55.
go back to reference Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279–85.PubMedCrossRef Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279–85.PubMedCrossRef
56.
go back to reference Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International 2011; August 18 [Epub ahead of print]. Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International 2011; August 18 [Epub ahead of print].
57.
go back to reference Preventive Services US. Task Force. Screening for osteoporosis: U.S.Preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356–64. Preventive Services US. Task Force. Screening for osteoporosis: U.S.Preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356–64.
58.
go back to reference Kanis JA, McCloskey E, Johansson H, et al. FRAX® with and without BMD. Calcified Tissue International 2011; [Epub ahead of print]. Kanis JA, McCloskey E, Johansson H, et al. FRAX® with and without BMD. Calcified Tissue International 2011; [Epub ahead of print].
59.
go back to reference Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279–85.PubMedCrossRef Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279–85.PubMedCrossRef
60.
go back to reference Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. A comparative study of using non hip bone density inputs with FRAX®. Osteoporos Int 2011;Oct 19. [Epub ahead of print]. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. A comparative study of using non hip bone density inputs with FRAX®. Osteoporos Int 2011;Oct 19. [Epub ahead of print].
64.
go back to reference Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809–16.PubMedCrossRef Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809–16.PubMedCrossRef
65.
go back to reference Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.CrossRef Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.CrossRef
66.
go back to reference Kanis article above, van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology: (Oxford) 2000;39:1383–89. Kanis article above, van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology: (Oxford) 2000;39:1383–89.
67.
go back to reference Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res. 2000;15(6):1006–13.PubMedCrossRef Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res. 2000;15(6):1006–13.PubMedCrossRef
68.
go back to reference Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. The J of Rheum. 1993;20(10):1666–9. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. The J of Rheum. 1993;20(10):1666–9.
69.
go back to reference Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J of Endocrin. 1997;137:209–17.CrossRef Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J of Endocrin. 1997;137:209–17.CrossRef
70.
go back to reference Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Annals of the Rheum Dis. 1995;54:49–52.CrossRef Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Annals of the Rheum Dis. 1995;54:49–52.CrossRef
71.
go back to reference De Vries F, Brache M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208–14.PubMedCrossRef De Vries F, Brache M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208–14.PubMedCrossRef
72.
go back to reference Johnell O, Kanis JA, Oden A, Johansson H, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–94.PubMedCrossRef Johnell O, Kanis JA, Oden A, Johansson H, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–94.PubMedCrossRef
73.
go back to reference Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467–75.PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467–75.PubMedCrossRef
74.
go back to reference Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468–89.PubMedCrossRef Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468–89.PubMedCrossRef
75.
go back to reference Jones G, Nguyen T, Sambrook PN, Kelly PJ, et al. A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol. 1995;22:932–6.PubMed Jones G, Nguyen T, Sambrook PN, Kelly PJ, et al. A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol. 1995;22:932–6.PubMed
76.
go back to reference Phillipov G, Phillips PJ. Skeletal site bone mineral density heterogeneity in women and men. Osteoporos Int. 2001;12:362–5.PubMedCrossRef Phillipov G, Phillips PJ. Skeletal site bone mineral density heterogeneity in women and men. Osteoporos Int. 2001;12:362–5.PubMedCrossRef
77.
go back to reference Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin Densitom. 2006;9:255–60.PubMedCrossRef Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin Densitom. 2006;9:255–60.PubMedCrossRef
78.
go back to reference Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343–50.PubMedCrossRef Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343–50.PubMedCrossRef
79.
go back to reference Leslie WD, Lix LM, Tsang JF, et al. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med 2007;1641–47. Leslie WD, Lix LM, Tsang JF, et al. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med 2007;1641–47.
80.
go back to reference Leslie WD, Lix LM. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res. 2011;26:460–7.PubMedCrossRef Leslie WD, Lix LM. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res. 2011;26:460–7.PubMedCrossRef
81.
go back to reference Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22:839–47.PubMedCrossRef Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22:839–47.PubMedCrossRef
82.
go back to reference Leslie WD, Kovacs CS, Olszynski WP, et al. Spine-Hip T-score difference predicts major osteoporositic fracture risk independent of FRAX®: a population-based report from CAMOS. J Clin Densitom. 2011;14(3):286–93.PubMedCrossRef Leslie WD, Kovacs CS, Olszynski WP, et al. Spine-Hip T-score difference predicts major osteoporositic fracture risk independent of FRAX®: a population-based report from CAMOS. J Clin Densitom. 2011;14(3):286–93.PubMedCrossRef
Metadata
Title
Assessment of Fracture Risk
Authors
Sanford Baim
William D. Leslie
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 1/2012
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-011-0093-9

Other articles of this Issue 1/2012

Current Osteoporosis Reports 1/2012 Go to the issue

Current Therapeutics (SL Silverman, Section Editor)

Vitamin D in the New Millennium

Current Therapeutics (SL Silverman, Section Editor)

Data from Extension Trials: Denosumab and Zoledronic Acid

Future Therapeutics (P Miller, Section Editor)

Nitric Oxide Donors for the Treatment of Osteoporosis